CVS
CVS Health Corporation
Stock
$85.20−0.49 (−0.57%)Close Oct 1, 2026
Cash flow statement
| Line | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $14.8B | $10.6B | $9.1B | $13.4B | $16.2B | $18.3B | $15.9B | $12.8B | $8.9B | $8.0B | $10.1B | $8.5B | $8.1B | $5.8B | $6.7B | $5.9B | $4.8B | $4.0B | $3.9B | $3.2B |
| Capital expenditures | $3.0B | $2.8B | $2.8B | $3.0B | $2.7B | $2.5B | $2.4B | $2.5B | $2.0B | $1.9B | $2.2B | $2.4B | $2.1B | $2.0B | $2.0B | $1.9B | $2.0B | $2.5B | $2.2B | $1.8B |
| Free cash flow | $11.8B | $7.8B | $6.3B | $10.4B | $13.5B | $15.7B | $13.4B | $10.4B | $6.8B | $6.1B | $7.9B | $6.2B | $6.0B | $3.8B | $4.6B | $4.0B | $2.8B | $1.5B | $1.8B | $1.4B |
| Stock-based compensation | $715M | $535M | $540M | $588M | $447M | $484M | $400M | $453M | $280M | $234M | $222M | $230M | $165M | $141M | $132M | $135M | $150M | $165M | $92M | $78M |
| Buybacks | — | $0 | $3.0B | $2.0B | $3.5B | $0 | $0 | $0 | $0 | $4.4B | $4.5B | $5.0B | $4.0B | $4.0B | $4.3B | $3.0B | $1.5B | $2.5B | $23M | $5.4B |
| Dividends paid | $3.4B | $3.4B | $3.4B | $3.1B | $2.9B | $2.6B | $2.6B | $2.6B | $2.0B | $2.0B | $1.8B | $1.6B | $1.3B | $1.1B | $829M | $674M | $479M | $439M | $383M | $323M |
| Dividends per share | $2.66 | $2.66 | $2.66 | $2.42 | $2.20 | $2.00 | $2.00 | $2.00 | $2.00 | $2.00 | $1.70 | $1.40 | $1.10 | $0.90 | $0.65 | $0.50 | $0.35 | $0.31 | $0.26 | $0.23 |
| Free cash flow margin | 2.8% | 1.9% | 1.7% | 2.9% | 4.2% | 5.4% | 5.0% | 4.0% | 3.5% | 3.3% | 4.5% | 4.0% | 4.3% | 3.0% | 3.8% | 3.7% | 2.9% | 1.5% | 2.0% | 1.9% |